Mineralys Therapeutics, Inc. (MLYS) News
Follow Mineralys Therapeutics, Inc. (MLYS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Mineralys Therapeutics Reports Third-Quarter 2026 Results and Update
The company says commercialization plans for lorundrostat are on track ahead of a December 22 PDUFA target date.
EQUITY | Nov 04, 2026, 09:09 PM UTC
M
Mineralys Reports Phase 3 Hypertension Data, Including 52% UACR Reduction
Launch-HTN data showed placebo-adjusted systolic blood pressure reductions of 9.6 mmHg in patients with CKD and 12.2 mmHg in those without CKD at week 12. UACR fell 52% versus placebo in the CKD group. FDA review for hyp
EQUITY | Oct 22, 2026, 10:43 PM UTC
L
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. NASDAQ:MLYS, a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in com
NEWS | Sep 29, 2026, 08:08 PM UTC
L
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. NASDAQ:MLYS, a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in com
NEWS | Sep 24, 2026, 08:11 PM UTC
H
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. NASDAQ:MLYS, a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in com
NEWS | Sep 23, 2026, 08:11 PM UTC
H
MLYS - Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
MLYS - Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
NEWS | Sep 23, 2026, 08:05 PM UTC
L
MLYS - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
MLYS - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 21, 2026, 08:05 PM UTC
L
MLYS: Lorundrostat prepares for launch with strong clinical data, parity access strategy, and full funding
Lorundrostat is advancing toward a December PDUFA date, supported by robust clinical data and a comprehensive commercial build-out targeting third- and fourth-line hypertension. The launch strategy emphasizes parity acce
EQUITY | Sep 09, 2026, 10:31 PM UTC
L
MLYS: Lorundrostat nears approval with strong data, broad market prep, and a focus on parity access
Lorundrostat is positioned for a December PDUFA, with robust clinical data supporting its use in third- and fourth-line hypertension. Commercial preparations, payer engagement, and a parity access strategy are in place,
EQUITY | Sep 09, 2026, 09:38 PM UTC
L
Mineralys Therapeutics reports inducement awards under Nasdaq Rule 5635(c)(4)
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. NASDAQ:MLYS, a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in com
EQUITY | Sep 09, 2026, 08:11 PM UTC
L
Mineralys Therapeutics to participate in Wells Fargo healthcare conference
Mineralys Therapeutics says it will participate in the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Aug 26, 2026, 12:07 PM UTC
L
Mineralys Therapeutics reports inducement award under Nasdaq Rule 5635(c)(4)
Mineralys Therapeutics (MLYS) reports an inducement award granted under Nasdaq Listing Rule 5635(c)(4), with no additional terms or magnitude provided in the feed.
REGULATION | Aug 13, 2026, 08:08 PM UTC
L
MLYS - Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MLYS - Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 11, 2026, 08:08 PM UTC
L
Mineralys Therapeutics Q2 EPS $(2.85) Misses $(0.55) Estimate
Mineralys Therapeutics Q2 EPS $(2.85) Misses $(0.55) Estimate
EARNINGS | Aug 11, 2026, 08:06 PM UTC
L
MLYS - Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 - Click
MLYS - Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
EARNINGS | Aug 04, 2026, 12:00 PM UTC